EDUARDO BELLO MARTINS
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
16 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 16
- The ORBITA trial: A point of view(2018) OLIVEIRA, Vitor Dornela de; GIUGNI, Fernando Rabioglio; MARTINS, Eduardo Bello; AZEVEDO, Diogo Freitas Cardoso de; LIMA, Eduardo Gomes; SERRANO JUNIOR, Carlos VicenteTreatment of stable coronary artery disease (CAD) relies on improved prognosis and relief of symptoms. National and international guidelines on CAD support the indication for revascularization in patients with limiting symptoms and refractory to drug treatment. Previous studies attested the efficacy of angioplasty to improve angina as well as the functional capacity of patients with symptomatic stable CAD. The ORBITA trial, recently published in an international journal, showed no benefit in terms of exercise tolerance compared to a placebo procedure in a population of single-vessel patients undergoing contemporary percutaneous coronary intervention. In this point of view article, the authors discuss the ORBITA trial regarding methodological issues, limitations and clinical applicability.
conferenceObject Application of SYNTAX score I, II and residual SYNTAX as predictors of long-term clinical outcomes after coronary artery bypass grafting(2019) MARTINS, E. B.; HUEB, W.; LIMA, E. G.; REZENDE, P. C.; GARZILLO, C. L.; CARVALHO, G. F.; CARVALHO, F. P. C.; LINHARES FILHO, J. P. P.; BATISTA, D. V.; SILVA, R. R.; BOROS, G. A. B.; AZEVEDO, D. F. C.; SERRANO JUNIOR, C. V.; RAMIRES, J. A. F.; KALIL FILHO, R.conferenceObject Impact of chronic kidney disease on diabetic patients with stable coronary disease undergoing surgery, angioplasty or medical treatment in a ten-year follow-up(2018) BATISTA, D. V.; HUEB, W.; LINHARES FILHO, J. P. P.; SILVA, R. R.; LIMA, E. G.; REZENDE, P. C.; MARTINS, E. B.; GARZILLO, C. L.; AZEVEDO, D. F. C.; RAMIRES, J. A. F.; KALIL FILHO, R.conferenceObject SYNTAX score and outcomes after coronary artery bypass grafting: a long-term follow-up analysis(2018) MARTINS, E. B.; HUEB, W.; SILVA, R. R.; LINHARES FILHO, J. P. P.; BATISTA, D. V.; RIBAS, F. F.; REZENDE, P. C.; LIMA, E. G.; AZEVEDO, D. F. C.; RAMIRES, J. A. F.; KALIL FILHO, R.- APPLICATION OF SYNTAX SCORE I, II AND RESIDUAL SYNTAX AS PREDICTORS OF LONG-TERM CLINICAL OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING(2019) MARTINS, Eduardo; HUEB, Whady; LIMA, Eduardo Gomes; CARVALHO, Guilherme Fernandes; DALLAZEN, Anderson Roberto; LINHARES FILHO, Jaime; BATISTA, Daniel Valente; SILVA, Rafael; AZEVEDO, Diogo Freitas Cardoso; REZENDE, Paulo; RAMIRES, Jose; KALIL FILHO, Roberto
- VERY LONG-TERM FOLLOW-UP OF DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE UNDERGOING ANGIOPLASTY WITH CONVENTIONAL AND DRUG-ELUTING STENTS(2019) MOCHA, Mauricio; RIBEIRO, Matheus Oliveira Laterza; CARVALHO, Guilherme Fernandes; LINHARES FILHO, Jaime; LIMA, Eduardo; HUEB, Whady; REZENDE, Paulo; BATISTA, Daniel Valente; MARTINS, Eduardo; AZEVEDO, Diogo Freitas Cardoso; GARZILLO, Cibele; KALIL-FILHO, Jose Ramires Roberto
- Significant association of SYNTAX score on release of cardiac biomarkers in uncomplicated post-revascularization procedures among patients with stable multivessel disease MASS-V Study group(2020) AZEVEDO, Diogo Freitas Cardoso de; HUEB, Whady; LIMA, Eduardo Gomes; REZENDE, Paulo Cury; LINHARES FILHO, Jaime Paula Pessoa; CARVALHO, Guilherme Fernandes de; MARTINS, Eduardo Bello; NOMURA, Cesar Higa; STRUNZ, Celia Maria Cassaro; SERRANO JUNIOR, Carlos Vicente; RAMIRES, Jose Antonio Franchini; KALIL FILHO, RobertoThis study investigated the relationship between angiographic complexities of coronary artery disease (CAD) assessed by SYNTAX Score synergy between percutaneous coronary intervention with taxus and cardiac surgery score (SYNTAX Score) and cardiac biomarker elevation after revascularization procedures. This is a post-hoc analysis of the medicine, angioplasty or surgery study V study of patients with stable CAD. High-sensitivity troponin 1 (hs-TnI) and creatinine kinase-muscle/brain (CK-MB) were assessed before and after cardiovascular procedures. Baselines SYNTAX Scores (SXScores) were calculated by blinded investigators to patient characteristics. Of the 202 patients studied, the mean SXScore was 21.25 +/- 9.24; 40.10 +/- 7.09 in the high SXScore group and 19.06 +/- 6.61 in low/mid SXscore group (P < .0001). Positive correlations existed between SXScore and median peaks after procedural hs-TnI (r = 0.18, P = .009) and CK-MB (r = 0.24, P = .001) levels. In patients with high SXScores (>= 33), the median peaks of post-procedural hs-TnI (P = .034)and CK-MB (P = .004) levels were higher than in low/mid SXScore group (<33).The release of hs-TnI at 6 (P = .002), 12 (P = .008), and 24 hours (P = .039) was higher in high SXScore group than in low/mid SXscore group (<33) as was the release of CK-MB at 6 (P < .0001), 12 (P < .0001), 24 (P = .001), 36 (P = .007), 48 (P = .008), and 72 hours (P = .023). After multivariable analysis, high SXScore was a significant independent predictor of release of CK-MB and hs-TnI peaks higher than the median. The increase in release of cardiac biomarkers was significantly associated with the extent of atherosclerosis identified by the SYNTAX Score.
conferenceObject Impact of glycated hemoglobin in diabetic patients with coronary artery disease undergoing surgery, angioplasty or clinical treatment in a very long-term follow-up(2018) LINHARES FILHO, J. P. P.; HUEB, W.; BATISTA, D. V.; SILVA, R. R.; LIMA, E. G.; REZENDE, P. C.; MARTINS, E. B.; GARZILLO, C. L.; AZEVEDO, D. F. C.; RAMIRES, J. A. F.; KALIL FILHO, R.conferenceObject Cardiac Biomarkers Elevation After Myocardial Revascularization Predicts Cardiovascular Prognosis. Long-Term Follow-Up of Mass-V Study(2018) LINHARES FILHO, Jaime P.; HUEB, Whady; V, Daniel Batista; LIMA, Eduardo G.; SILVA, Rafael R.; REZENDE, Paulo C.; STRUNZ, Celia M.; MARTINS, Eduardo B.; GARZILLO, Cibele L.; AZEVEDO, Diogo F.; DALLAZEN, Anderson R.; RIBAS, Fernando F.; RAMIRES, Jose A.; KALIL FILHO, Roberto- Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial(2020) LIMA, Eduardo Gomes; CHARYTAN, David M.; HUEB, Whady; AZEVEDO, Diogo Freitas Cardoso de; GARZILLO, Cibele Larrosa; FAVARATO, Desiderio; LINHARES FILHO, Jaime Paula Pessoa; MARTINS, Eduardo Bello; BATISTA, Daniel Valente; REZENDE, Paulo Cury; HUEB, Alexandre Ciappina; RAMIRES, Jose Antonio Franchini; KALIL FILHO, RobertoBackground. Chronic kidney disease (CKD) is associated with a worse prognosis in patients with stable coronary artery disease (CAD); however, there is limited randomized data on long-term outcomes of CAD therapies in these patients. We evaluated long-term outcomes of CKD patients with CAD who underwent randomized therapy with medical treatment (MT) alone, percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). Methods. Baseline estimated glomerular filtration rate (eGFR) was obtained in 611 patients randomized to one of three therapeutic strategies in the Medicine, Angioplasty, or Surgery Study II trial. Patients were categorized in preserved renal function and mild or moderate CKD groups depending on their eGFR (>= 90, 89-60 and 59-30 mL/min/1.73 m(2), respectively). The primary clinical endpoint, a composite of overall death and myocardial infarction, and its individual components were analyzed using proportional hazards regression (Clinical Trial registration information: http://www.controlled-trials.com.Registration number: ISRCTN66068876). Results. Of 611 patients, 112 (18%) had preserved eGFR, 349 (57%) mild dysfunction and 150 (25%) moderate dysfunction. The primary endpoint occurred in 29.5, 32.4 and 44.7% (P = 0.02) for preserved eGFR, mild CKD and moderate CKD, respectively. Overall mortality incidence was 18.7, 23.8 and 39.3% for preserved eGFR, mild CKD and moderate CKD, respectively (P = 0.001). For preserved eGFR, there was no significant difference in outcomes between therapies. For mild CKD, the primary event rate was 29.4% for PCI, 29.1% for CABG and 41.1% for MT (P = 0.006) [adjusted hazard ratio (HR) = 0.26, 95% confidence interval (CI) 0.07-0.88; P = 0.03 for PCI versus MT; and adjusted HR = 0.48; 95% CI 0.31-0.76; P = 0.002 for CABG versus MT]. We also observed higher mortality rates in the MT group (28.6%) compared with PCI (24.1%) and CABG (19.0%) groups (P = 0.015) among mild CKD subjects (adjusted HR = 0.44, 95% CI 0.25-0.76; P = 0.003 for CABG versus MT; adjusted HR = 0.56, 95% CI 0.07-4.28; P = 0.58 for PCI versus MT). Results were similar with moderate CKD group but did not achieve significance. Conclusions. Coronary interventional therapy, both PCI and CABG, is associated with lower rates of events compared with MT in mild CKD patients >10 years of follow-up. More study is needed to confirm these benefits in moderate CKD.